CURIS INC

CRIS stock represents shares of Curis, Inc., a biotechnology company focused on developing and commercializing innovative cancer therapies. The ticker trades on the Nasdaq Capital Market under the symbol CRIS. As a clinical-stage biopharmaceutical firm, its value is closely tied to the progress of its drug pipeline rather than marketed products. Investors often track CRIS for its potential in targeted oncology treatments.

Curis, Inc. is a biotechnology company that discovers and develops drug candidates for cancer treatment. Its pipeline includes targeted therapies aimed at signaling pathways involved in tumor growth. The company primarily conducts research and clinical trials, often in collaboration with larger pharmaceutical partners. CRIS does not currently market any approved products, so its operations center on advancing experimental drugs through development stages.

The 52-week range shows the lowest and highest prices at which CRIS has traded over the past year. This metric helps investors gauge historical price volatility and where the current price sits relative to that span. For the latest exact low and high values, please refer to the 52-week range data displayed on this CRIS stock page, as these figures change with market activity.

Evaluating CRIS valuation is complex because the company is clinical-stage and may not have consistent revenue or earnings. Traditional metrics like the price-to-earnings ratio are often not meaningful. Instead, investors may consider cash reserves, pipeline progress, and potential market opportunities for its drug candidates. Comparing CRIS to similar biotech peers and reviewing its financial statements can provide context for its current valuation.

CRIS stock can be traded in pre-market and after-hours sessions through many brokerage platforms, though liquidity is typically lower than during regular trading hours. Extended-hours trading may involve wider spreads and higher volatility. The regular market session for Nasdaq-listed stocks runs from 9:30 AM to 4:00 PM Eastern Time. Check with your broker for specific availability and any associated fees.

As a clinical-stage biotech, CRIS faces significant risks including clinical trial failures, regulatory delays, and the need for additional capital to fund research. Its stock price can be highly volatile around data announcements. Competition from other oncology therapies and reliance on collaboration partners also pose challenges. Additionally, the company may not achieve profitability if its drug candidates do not receive approval or gain market acceptance.